Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial

•Exploratory analyses suggest PFS benefit may be derived from veliparib + carboplatin/paclitaxel and veliparib monotherapy.•PFS hazard ratios were similar in patients who continued to monotherapy after 1-6 or 7-12 cycles of combination therapy.•Veliparib monotherapy led to adverse events that were primarily gastrointestinal with a low incidence of cytopenias.